期刊文献+

组蛋白去乙酰化酶抑制剂SAHA体外抑制人卵巢癌SKOV3细胞的实验研究 被引量:3

SAHA inhibition of the human ovarian cancer cell line SKOV3 in vitro
下载PDF
导出
摘要 目的:观察组蛋白去乙酰化酶抑制剂辛二酰苯胺异羟肟酸(suberoylanilide hydroxamic acid,SAHA)体外对人卵巢癌SKOV3细胞增殖和凋亡的作用,并探讨其可能机制。方法:体外应用SAHA作用于人卵巢癌SKOV3细胞,MTT法检测细胞增殖,流式细胞术检测细胞凋亡率。Western blot法检测细胞内组蛋白H4乙酰化水平,实时定量PCR方法检测p21、Bcl-2和Bax基因mRNA表达。结果:经SAHA作用后的人卵巢癌SKOV3细胞生长受到抑制,细胞凋亡增加(各实验组与对照组比较,均P<0.05),呈剂量依赖性;同时细胞内组蛋白H4乙酰化水平增加,p21基因和Bax基因mRNA表达增加(各实验组与对照组比较,均P<0.05),呈剂量依赖性,Bcl-2基因表达无明显变化(各实验组与对照组比较,均P>0.05)。结论:SAHA体外可抑制人卵巢癌SKOV3细胞增殖和诱导SKOV3细胞凋亡,提高组蛋白乙酰化水平,增加p21和Bax基因表达可能是其作用机制之一。 Objective: This study aimed to determine the effects of suberoylanilide hydroxamic acid (SAHA) on the cell proliferation and apoptosis of the human ovarian cancer cell line SKOV3. The possible underlying mechanisms were also investigated. Methods: The SKOV3 cells were treated with the histone deacetylase inhibitor SAHA. Cell growth was estimated by using the MTT assay, whereas the cell apoptosis rate was estimated by flow cytometry. Furthermore, Western blot analysis was used to detect the acetyl level ofhistone H4, whereas real-time PCR was used to detect the mRNA of p21, Bcl-2, and Bax. Results: After treatment with SAHA, cellu- lar growth was decreased, whereas cell apoptosis increased in SKOV3 cells in a concentration dependent manner (the different SAHA groups vs. the control group, P〈0.05), Meanwhile, the acetyl level of histone H4 was increased. The mRNA of p21 and Bax were simi- larly increased in a concentration dependent manner (the different SAHA groups vs. the control group, P〈0.05). By contrast, the mRNA of Bcl-2 was not significantly changed (the different SAHA groups vs. the control group, P〉0.05). Conclusion: SAHA could effectively inhibit cellular proliferation and induce apoptosis in ovarian cancer SKOV3 cells in vitro. The increased acetyl level of the histones could enhance the p21 and Bax gene expression, as one of its mechanisms.
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2013年第12期698-701,共4页 Chinese Journal of Clinical Oncology
关键词 卵巢癌 辛二酰苯胺异羟肟酸 增殖 凋亡 ovarian cancer, suberoylanilide hydroxamic acid, proliferation, apoptosis
  • 相关文献

参考文献15

  • 1LIU S. Epigenetices advancing personalized nanomedicine in can- cer therapy[J]. Adv Drug Deliv Rev, 2012, 64(13):1532-1543.
  • 2Kroep JR. Advance in epithelial ovarian cancer therapy[J]. Curr Pharm Des, 2012, 18(25) :3735--3740.
  • 3Hagelkruys A, Sawicka A, Selser C, et al. The biology of HDAC in cancer; the nuclear and epigenetic components[J]. Handb Exp Pharmacol, 2011, 206:13--37.
  • 4韩艳,张美花,金铁峰,张爽,玄延花,林贞花.HDAC1和HDAC6蛋白过表达在卵巢浆液性癌中的临床病理学意义[J].临床与实验病理学杂志,2010,26(4):394-396. 被引量:8
  • 5Kubo M, Kanaya N, Petrossian K, et ai. Inhibition of the prolifera- tion of acquired aromatase inhibitor--resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)[J]. Breast Can- cer Res Treat, 2013, 137(1):93-107.
  • 6Abaza MS, Bahman AM, AI-Atfiyah RJ, et al. Synergistic induc- tion of apoptosis and chemosensitization of human colorectal cancer cells by histone deacetylase inhibitor, scriptaid, and proteasome in_hibitors: potential mechanisms of action[J]. Turnout Biol, 2012, 33 (6):1951--1972.
  • 7Bai LY, Omar HA, Chiu CF, et al. Andtumor effects of (S)-HDAC42, a phenylbutyrate--derived histone deacetylase inhibitor, in multiple myeloma cells[J]. Cancer Chemother Pharmacol, 2011,68(2):489-496.
  • 8Chen MY, Liao WS, Lu Z, et al. Decitabine and suberoylanilide hy- droxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor sup- pressor genes, apoptosis, G2/M arrest, and autophagy[J]. Cancer, 2011, 117(19):4424-4438.
  • 9Dietrich CS 3rd, Greenberg VL, DeSimone CP, et al. Suberoylanilide hydroxamic acid (SAHA) potentiates paclitaxel--induced apoptosis in ovarian cancer cell lines[J]. Gynecol Oncol, 2010, 116(1):126-130.
  • 10Cooper AL, Greenberg VL, Lancaster PS, et al. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hy- droxamic acid (SAHA) and paclitaxel in ovarian cancer[J]. Gynecol Oncol, 2007, 104(3) :596-601.

二级参考文献12

  • 1陈刚,王蓓蓓,李辅军,刘德艳,周剑锋,卢运萍,马丁.HDAC抑制剂TSA增强卵巢癌细胞株A2780对腺病毒基因转染效率的体外研究[J].癌症,2005,24(10):1196-1200. 被引量:6
  • 2周蔚,李留霞.卵巢癌的靶向基因治疗研究进展[J].国外医学(妇产科学分册),2006,33(5):324-327. 被引量:3
  • 3Hildmann C,Wegener D,Riester D,et al.Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases[J].J Biotechnol,2006,124(1):258-70.
  • 4Matthias P,Youshida M,Khochbin S.HDAC6 a new cellular stress surveillance factor[J].Cell Cycle,2008,7(1):7-10.
  • 5Kwon S,Zhang Y,Matthias P.The deacetylase HDAC6 is a novel critical component of stress granules involved in the stress response[J].Genes Dev,2007,21(24):3381-94.
  • 6Zhang Z,Yamashita H,Toyama T,et al.HDAC6 expression is correlated with better survival in breast cancer[J].Clin Cancer Res,2004,10(20):6962-8.
  • 7Lin Z,Shen X,Jin Z,et al.HPV genotyping by oligonucleotide microarray and p16INK4A expression in the uterine cervical intraepithelial neoplasm and invasive carcinoma in Korean women[J].Pathol Int,2005,55(8):491-6.
  • 8Serrano-Olvera A,Duenas-Gonzalez A,Gallardo-Rincon D,et al.Prognostic,predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer[J].Cancer Treat Rev,2006,32(3):180-90.
  • 9Sakuma T,Uzama K,Onda T,et al.Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma[J].Int J Oncol,2006,29(1):117-24.
  • 10Bazzaro M,Lin Z,Santillan A,et al.Ubiquitin proteasome system stress underlies synergistic Killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor[J].Clin Cancer Res,2008,14(22):7340-7.

共引文献7

同被引文献6

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部